Next Phase Newsletter

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat. 
 
The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data. 
 
The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

 A healthcare venture capital firm established in 2019 with offices in US and China focuses on early- and growth-stage biotech and medtech companies. Initial check sizes range from USD $3-5M for Series A and B, and USD $10M+ for Series C and beyond. Currently, the firm has 3 funds under management, exceeding USD $600M AUM. The current fund is focused on U.S. companies. The firm can act as a lead or co-investor. 
 
The firm is especially interested in biotherapeutic innovations and would like to see positive data that has come out of clinical trials. The firm is open to all indications but has a high interest in oncology, immunology, and chronic disease. 
 
The firm likes to see experienced management teams, especially those with founders that have had previous success. The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Europe-based impact fund is investing from an evergreen fund. The firm is focused on investing in pre-clinical companies in pre-seed and seed rounds. The firm particularly likes companies with an IP component – patent or patent pending. The typical check size is 100K-500K euros, and the firm is looking to make 7-10 investments within the next year. The firm typically acts as a syndicate, not usually leading rounds. The firm will invest globally, with a particular focus on the USA and Europe. 
 
The firm invests in two main verticals – human preservation and planet health. Within life sciences, the firm invests primarily in therapeutics and biopharma, and will invest in diagnostics, medical devices, and digital health. The firm likes to look at companies offering a unique factor, such as specialized biopharma or drug delivery mechanism. The firm has a particular focus on CNS, oncology, and alternative cell therapies. 
 
The firm has no specific team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A European life science VC fund manager invests across all healthcare verticals and stages, in products with the potential to address unmet medical needs. The firm invests throughout Europe, with a focus on the Nordics and DACH, and flexibility for 1-2 US investments. Initial investments are typically €7-8 million. 
 
The firm invests across the life science sector, including therapeutics, devices and diagnostics. The firm only invests in products that are subject to medical regulation. The firm will consider any indication or modality. The firm prefers to invest in assets that are at least ready to go into clinical trials. 
 
The firm is a European investor with a focus on companies based in Europe but will consider US investments with a US lead investor. While the firm does not exclude any areas of opportunity, there is a focus on de-risked assets and areas in which the execution and regulatory risk for the asset is reduced. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A tech-driven pharmaceutical company based in the U.S. leverages its AI-powered drug development platform, the firm seeks to acquire promising drug candidates and develop them in-house faster and more efficiently than industry norms. The firm is interested in early clinical-stage therapeutic assets, and its typical deal structures include acquisitions and in-licensing. While equity investments are occasionally possible, the firm prefers to take a majority share and does not typically act as a minority investor. The firm is open to opportunities globally. 
 
The firm is interested in traditional therapeutic assets such as small molecules and biologics, with a primary focus on immunology, dermatology, and orphan diseases. Other indications of interest include CNS, cardiovascular, and metabolic diseases. The firm generally avoids cell therapy and oncology. As for development phases, the earliest the firm will consider is within 12 months of IND, with no limitation on how late the asset is in the clinical stage. 
 
The firm does not have specific requirements for a company’s management team, as the firm aims to take over the asset and typically does not act as a minority investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment management firm is led by partners who have been co-founders / founding executives of successfully exited healthtech companies, with expertise spanning various fields of life sciences. The firm is an active investor in life sciences & healthcare, and is open to all stages of development. Typical investment size is $1-2M for early stage companies, though the size can go up to over $10M in later-stage companies. The firm is open to global opportunities. 
 
The firm invests broadly across therapeutics, medical devices, diagnostics, and digital health, with stronger interests in the first 3 sectors listed. The firm seeks first-in-class / best-in-class technologies that address unmet medical need. In terms of indication, oncology is less of a priority, but is still considered. The firm is open to reviewing both pre-clinical and clinical stage technologies. 
 
The firm seeks to work with companies backed by a committed management team. The firm can act as either a lead/co-lead or co-investor. The firm is capable of getting other family offices involved in forming a syndicate on a deal-by-deal basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.